Approach

Value investing, at growth stage.

Discipline on entry valuation. A defined path to exit. Both primary and secondary transactions, held to the same standard.

What we target

Market leaders, not market hopefuls.

01

Best-in-class products

Market-ready, with proven use cases and strong intellectual property. A defensible moat — or years ahead of credible competition.

02

Real revenue

Established and growing revenue. EBITDA-positive or at a visible inflection point. Past product-market fit, before the IPO bid.

03

Mission-driven leadership

Strong teams with a clear business model. Companies that promote partnership and synergy across the broader portfolio.

Where we enter

Past proof of concept, pre-hype.

The maturity cycle of a private company can be read in fund-raising phases. Pre-revenue rounds carry too much execution risk for our framework; late-stage rounds typically price in the entire arc to public markets. We enter in between — the inflection point where revenue is real, EBITDA is visible, and entry valuations still leave room.

PhasePre-Rosemoor
High risk.
Pre-revenue or unproven model. Too early for our framework.
PhaseOptimal entry
Growth.
Real revenue, positive EBITDA visibility, valuations that still leave room. Where Rosemoor deploys.
PhaseBeyond Rosemoor
Liquidity.
Late-stage and proven. Pricing typically too rich for value discipline.

Identifying an excellent company isn't enough. The entry valuation is just as crucial.

Investment Philosophy · Rosemoor Capital
How we transact

Primary and secondary, on the same terms.

Rosemoor invests in both primary rounds and secondary-market transactions. The secondary market often offers price advantages — sellers act on their need for liquidity, not on conviction about the asset. Short-term volatility and regulatory shocks create dislocation that patient capital can underwrite. We apply the same value discipline across both routes.

Primary

Direct rounds, on conviction.

Participating in priced rounds led by best-in-class venture firms, where our diligence, network, and post-investment engagement add value beyond capital.

Secondary

Patient capital, asymmetric pricing.

Buying from long-term employees, GPs returning capital, or sellers acting on liquidity needs. Same diligence, same standards — pricing that reflects the seller's timeline rather than the asset's value.

How it ends

A defined exit strategy.

IPO, strategic acquisition, or tender offer — every position is underwritten with an articulable strategy to exit, identified before we enter. We invest with the route to liquidity in mind, not a calendar promise.

Discuss with Us